

Is It Time to Consider Photobiomodulation As a Drug Equivalent?

Tiina Karu, PhD, DrSci

THE QUESTION OF WHETHER photobiomodulation should be used as a drug equivalent arose in my mind after listening to presentations at the recent conference of the World Association for Laser Therapy (WALT)-2012 (Gold Coast City, Australia), and later at home when searching MEDLINE® for the years 2009–2012. Photobiomodulation (earlier terms: low level laser therapy, LLLT, laser biostimulation) has been used in clinical practice for >40 years by now, and its action mechanisms on cellular and molecular levels have been studied for >30 years. Enthusiastic medical specialists successfully used photobiomodulation in treating healing-resistant wounds and ulcers (e.g., chronic diabetic ulcers), in pain management, and in spinal cord and nervous system injuries when other methods had had limited success.¹ However, photobiomodulation is still not a part of mainstream medicine. The goal of the present Editorial is to highlight some important recent developments in clinical applications and in studies of cellular and molecular mechanisms behind the clinical findings.

One of the impressive and perspective challenges for photobiomodulation is its use in cases of Parkinson's disease. Research in recent years evidenced that neuroprotective treatment with red and near infrared radiation (NIR) prevented mitochondrial dysfunction and dopamine loss in Parkinson's disease patients.² In another set of experiments, NIR normalized mitochondrial movement and axon transport, as well as stimulating respiration in cytoplasmic hybrid ("cybrid") neurons.^{3,4} It is important to recall that reduced axonal transport contributes substantially to the degeneration of neuronal processes in Parkinson's disease.

Another development in recent years is the successful stimulation of stem cells with red and NIR radiation. One example is the treatment of myocardial infarction. The heart has been considered a post-mitotic organ lacking the capacity for self-renewal after injury. Surprisingly enough, human cardiac stem cells, in combination with bone marrow mesenchymal stem cells, were found to reduce infarct size and restore cardiac functions after myocardial infarction.⁵ This positive effect can even be increased by irradiation of stem cells. Mesenchymal stem cells were derived from bone marrow and adipose tissue, and stimulated by irradiation at $\lambda = 810$ nm. Implantation of irradiated cells into the infarcted rat heart resulted in an ~50% decrease in cardiac infarct size.⁶ An increase in proliferation rates and membrane potential was established after 532 nm irradiation of adipose

tissue-derived stem cells.⁷ A recent review⁸ summarized data about enhancement of the proliferation of various cultured cell lines, including stem cells, as well as cell lines used for the production of viral vaccines and hybrid cell lines. The review⁸ underlined that photobiomodulation improves the proliferation of cells without causing any cytotoxic effects. One has to emphasize that laser therapy shares none of the risks associated with stem cell therapy, requires no anesthesia, and is painless.⁹ The optimal light parameters in this review⁸ were found to be as follows: doses were 0.5–4.0 J/cm² and wavelengths ranged from 600 to 700 nm. It is important to recall that, in this particular wavelength range, two peaks in absorption and action spectra connected with activation of cytochrome c oxidase (the primary photoacceptor for photobiomodulation effects) are situated.¹⁰ The peak at 620 nm belongs to reduced Cu_A, and that at 680 nm, to oxidized Cu_B atoms in cytochrome c oxidase molecule.¹¹

The treatment of vitiligo (a depigmentary disorder) remains a challenge for clinical dermatologists. He-Ne laser irradiation was found to stimulate melanocyte proliferation.¹² The expression of phosphorylated cyclic-adenosine monophosphate (AMP) response element-binding protein, an important regulator of melanocyte growth, was upregulated by He-Ne laser treatment. He-Ne laser irradiation imparted a growth stimulatory effect on functional melanocytes via mitochondria-related pathways.¹²

Irradiation with red light caused gene and noncoding RNA regulation for photoacceptor protection in the retina. This finding may open a new challenge for photobiomodulation.¹³

One of the major dose-limiting effects of chemotherapy drugs is oral mucositis of treated patients. Oral mucositis can affect up to 100% of patients undergoing high-dose chemotherapy and hematopoietic stem cell transplantation. Photobiomodulation can improve tissue repair and immune response in these patients.¹⁴

Photobiomodulation has been shown to improve functional outcome after surgical intervention to repair injured nerves. LED irradiation at 810 nm accelerated functional recovery and improved the quality of nerve regeneration after autograft repair of severely injured peripheral nerves.¹⁵

Forehead treatments with NIR reversed major depression and anxiety.¹⁶ Transcranial NIR laser therapy was investigated

as a new neuroprotective treatment for acute ischemic stroke.¹⁷ The authors of these studies believe that the irradiation promoted functional and behavioral recovery via cellular mitochondrial mechanisms, as well as by enhancing cerebral blood flow.

Photobiomodulation altered cardiac cytokine expression following acute myocardial infarction,¹⁸ as well as protected cardiomyocytes from hypoxia and reoxygenation injury via nitric oxide-dependent mitochondrial mechanisms.¹⁹

The analgetic effects of photobiomodulation have been studied for years, and are documented rather well.²⁰ Light treatment ($\lambda = 635$ nm) of open skin wounds of corticosteroid-treated diabetic rats was useless, as compared with nonsteroid laser treatment, in which case a significant acceleration of epitalization and collagen synthesis was observed.²¹ This finding could probably explain why in some clinical cases the laser treatment of wounds has a low efficiency. At the same time, irradiation at 660 nm was effective for collagen production in diabetic wounded fibroblasts.²²

I will conclude by discussing "mitochondrial mechanisms of photobiomodulation,"²³ the term used widely in recent years for molecular and cellular mechanisms of light action. The rather old suggestion^{10,11} that the photoacceptor for photobiomodulation effects is cytochrome c oxidase has been confirmed by now.²⁴ The new data²⁵ support the old conclusion that photobiomodulation is more pronounced in ill or otherwise stressed cells, as compared with healthy cells with plenty of oxygen available.²⁶ The terminal enzyme of the mitochondrial respiratory chain and its electronic excitation by light with proper parameters causes retrograde light-sensitive cellular signaling events to transport the light signal from mitochondria to the nucleus to cause gene expression.²⁷ The gene expression events caused by irradiation are confirmed, and have been studied in more detail in recent years.^{28,29}

Acknowledgments

This study was supported by the grant No 11-02-00295 RFFI.

References

1. Tuner, J., and Hode, L. (2011). *The laser therapy handbook*. Grängesberg: Prima Books.
2. Shaw, V.E., Spana, S., Ashkan, K., Benabid AL, Stone J, Baker GE, and Mitrofanis, J. (2010). Neuroprotection in midbrain dopaminergic cells in MPTP-treated mice after near-infrared light treatment. *J. Comp. Neurol.* 518, 25–40.
3. Trimmer, P.A., and Benett, J.P. (2009). The cybrid model of sporadic Parkinson's disease. *Exp. Neurol.* 218, 320–325.
4. Trimmer, P.A., Schwarz, K.M., Borland, M.K., De Taboada, L., Streeter, J., and Oron, U. (2009). Reduced axonal transport in Parkinson's disease cybrid neurites is restored by light therapy. *Mol. Neurodegener.* 4, 26–40.
5. Williams, A.R., Hatzistergos, K.E., Addicott, B., McCall, F., Carvalho, D., Suncion, V. and Morales, A.R., Da Silva, J., Sussman, M.A., Heldman, A.W., and Hare, J.M. (2013). Enhanced effect of combining human cardiac stem cells in bone marrow mesenchymal stem cells to reduce infarct size and to restore cardiac function after myocardial infarction. *Circulation* 127, 213–223.
6. Tuby, H., Maltz, L., and Oron, U. (2008). Implantation of low-level laser irradiated mesenchymal stem cells into the infarcted rat heart is associated with reduction in infarct size and enhanced angiogenesis. *Photomed. Laser Surg.* 27, 227–234.
7. Anwer, A.G., Gosnell, M.E., Perinchery, S.M., Inglis, D.W., and Goldys, E.M. (2012). Visible 532 nm laser irradiation of human adipose tissue-derived stem cells: effect on proliferation rates, mitochondria membrane potential and auto-fluorescence. *Lasers Surg. Med.* 44, 769–778.
8. AlGhandi, A., Kumar, A., and Moussa, N.A. (2012). Low-level laser therapy: a useful technique for enhancing the proliferation of various cultured cells. *Lasers Med. Sci.* 27, 237–249.
9. Malliaras, K., Zhang, Y., Senfeld, J., Galang, G., Tseliou, E., Cheng, K., Sun, B., Aminzadeh, M., and Marban, E. (2013). Cardiomyocyte proliferation and progenitor cell recruitment underlie therapeutic regeneration after myocardial infarction in the adult mouse heart. *EMBO Molec. Med.* 5, 191–209.
10. Karu, T.I., Pyatibrat, L.V., Kolyakov, S.F., and Afanasyeva, N.I. (2005). Absorption measurements of a cell monolayer relevant to phototherapy: reduction of cytochrome c oxidase under near IR radiation. *J. Photochem. Photobiol. B Biol.* 81, 98–106.
11. Karu, T.I. (2010). Multiple roles of cytochrome c oxidase in mammalian cells under action of red and IR-A radiation. *IUBMB Life* 62, 607–610.
12. Lan, C.C.E., Wu, C.-S., Chiou, Y.-H., Chiang, T.Y., and Yu, H.S. (2009). Low-energy He-Ne laser induced melanocyte proliferation via interaction with type IV collagen: visible light as a therapeutic option for vitiligo. *Br. J. Dermatol.* 161, 273–280.
13. Natoli, R., Zhu, Y., Valter, K., Bisti, S., Eells, J., and Stone, J. (2010). Gene and noncoding RNA regulation underlying photoreceptor protection: Microarray study of dietary antioxidant saffron and photobiomodulation in rat retina. *Mol. Vis.* 16, 1801–1822.
14. Bjordal, J.M., Bensadoun, R.-J., Tuner, J., Frigo, L., Gjerde, K., and Lopes-Martins, R.A. (2011). A systematic review with meta-analysis of the effect of low-level laser therapy (LLLT) in cancer therapy-induced oral mucositis. *Support. Care Cancer* 19, 1069–1077.
15. Moges, H., Wu, X., McCoy, J., Vasconcelos, O.M., Bryant, H., Grunberg, N.E., and Anders, J.J. (2011). Effect of 810 nm light on nerve regeneration after autograft repair of severely injured rat median nerve. *Lasers Surg. Med.* 43, 901–906.
16. Schiffer, F., Johnston, A.L., Ravichandean, C., Polcari, A., Teicher, M.H., Webb, R.H., and Hamblin, M.R. (2009). Psychological benefits 2 and 4 weeks after a single treatment with NIR to the forehead: a pilot study of 10 patients with major depression and anxiety. *Behav. Brain Funct.* 5, 46.
17. Lapchak, P.A. (2010). Taking a light approach to treating acute ischemic stroke patients: transcranial near infrared laser therapy in translational science. *Ann. Med.* 42, 576–586.
18. Yang, Z., Wu, Y., Zhang, H., Jin, P., Wang, W., Hou, J., Wei, Y., and Hu, S. (2011). Low-level laser irradiation alters cardiac cytokine expression following acute myocardial infarction: a potential mechanism for laser therapy. *Photomed. Laser Surg.* 29, 391–398.
19. Zhang, R., Yasushi, M., Pratt, P.F., Lohr, N., Warltier, D.C., Whelan, H.T., Zhu, D., Jacobs, E.R., Medhora, M., and Bienenberger, M. (2009). Near infrared light protects cardiomyocytes from hypoxia and reoxygenation injury by a nitric oxide dependent mechanism. *J. Mol. Cell Cardiol.* 46, 4–14.

20. Chow, R., Arwati, P., Laakso, L., Bjordal, J., and Baxter, G. (2011). Inhibition and relevance to analgetic affects: A systematic review. *Photomed. Laser Surg.* 29, 365–381.
21. Gal, P., Mokry, M., Vidinsky, B., Kilik, R., Depta, F., Harakalova, M., Longauer, F., Mozel, S., and Sabo, J. (2009). Effect of equal daily doses achieved by different power densities of low-level laser therapy at 635 nm on open skin wound healing in normal and corticosteroid-treated rats. *Lasers Med. Sci.*, 24, 539–547.
22. Ayuk, S.M., Houreld, N.N., and Abrahamse, H. (2012). Collagen production in diabetic wounded fibroblasts in response to low-intensity laser radiation at 660 nm. *Diabetes Technol. Ther.* 14, 1110–1117.
23. Karu, T.I. (2010). Mitochondrial mechanisms of photobiomodulation in context of new data about multiple roles of ATP. *Photomed. Laser Surg.*, 28, 159–160.
24. Hamblin, M.R. (2010). Introduction to experimental and clinical studies using low level laser (light) therapy (LLLT). *Lasers Surg. Med.* 42, 447–449.
25. Masha, R.T., Houreld, N., and Abrahamse, H. (2012). Low-intensity laser irradiation at 660 nm and stimulates cytochrome c oxidase in stressed fibroblast cells. *Lasers Surg. Med.* 44, 429–434.
26. Karu, T., (2007). Ten lectures on basic science of laser phototherapy. Grängesberg: Prima Books AB.
27. Karu, T., and Pyatibrat, L. (2011). Gene expression under laser and light-emitting diodes radiation for modulation of cell adhesion: possible applications for biotechnology. *IUBMB Life* 63, 747–753.
28. McDaniel, D.H., Weiss, R.A., Geronemus, R.G., Mazur, C., Wilson, S., and Weiss, M.A. (2010) Varying ratios of wavelengths in dual wavelength LED photomodulation alters gene expression profiles in human skin fibroblasts. *Laser Surg. Med.* 42, 540–545.
29. Masha, R.T., Houreld, N.N., and Abrahamse, H. (2013). Low intensity laser irradiation at 660 nm stimulates transcription of genes involved in electron transport chain. *Photomed. Laser Surg.* 31, 47–53.

Address correspondence to:

*Tiina Karu
Institute of Laser and Information Technologies
of Russian Academy of Sciences
142190 Troitsk
Moscow
Pionerskaya Str., 2
Russian Federation*

E-mail: tkaru@isan.troitsk.ru